• Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that ANAVEX 2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets.

• Scientific Paper Highlights:

  • Sigma-1 receptor (SIGMAR1)'s expression increases with age. However, in Alzheimer's disease (AD), it decreases and coincides with an age-related decrease in autophagy.

  • The SIGMAR1 may compensate for the loss of receptors and autophagic machinery during healthy aging.

  • ANAVEX-compounds activate SIGMAR1 and induce autophagy, a phenomenon that clears damaged cellular organelles and misfolded proteins.

  • Activation of the SIGMAR1 can induce cytoprotective autophagic pathways.

  • ANAVEX-compounds have also exhibited to block toxic Aβ, tau, and neuroinflammation.

• Price Action: AVXL shares are up 20.7% at $18.71 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

• Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.